Led · Equity · Mar 2026

Everdrone develops autonomous drone systems that deliver life-saving medical equipment—such as automated external defibrillators (AEDs)—to emergency scenes and provide real-time video support to emergency dispatchers. The company leverages proprietary technology to enable these deliveries and to operate in regulatory-compliant urban settings. Everdrone collaborates with public authorities to integrate its drone systems with existing emergency infrastructure. Led by CEO Mats Sällström and based in Askim, Sweden, the company plans to use the newly raised funds to expand operations and further development efforts. The articles do not disclose revenue, user counts, or past funding details.

Led · Equity · Feb 2026

NEOGAP Therapeutics AB is building an autologous cell therapy platform called personalised Tumour Trained Lymphocytes (pTTL), which amplifies a patient’s own tumour-reactive T cells to fight cancer. The therapy combines the company’s proprietary PIOR and EpiTCer technologies with advanced DNA sequencing to create a precision, patient-specific product for solid tumours. NEOGAP is currently running a first-in-human Phase I/II trial evaluating safety and tolerability of pTTL in patients with advanced colorectal cancer; several patients have already been treated and initial safety data indicate good tolerability. Sweden’s Medical Products Agency has authorised dosing all study participants at the full dose, enabling a more efficient trial design. In parallel, the company has used support from its EU EIC grant to develop a scaled manufacturing plan together with CDMO NorthX Biologics in preparation for later-stage studies and commercialisation. Recent exploratory clinical signals are described as promising, and management is preparing for the next step in clinical development. No revenue or user metrics were disclosed in the article.

Participated · Equity · Feb 2024

Capitainer develops intelligent solutions for self-sampling of blood and plasma, positioning itself in the self-sampling diagnostics market. The company’s product portfolio is described as disruptive and supported by solid data. Capitainer plans to scale up production capacity, enhance sales and marketing, and launch new products as part of its expansion. Management specifically cites efforts to grow in the EU and US markets. The company has secured a significant investment to support these initiatives and growth plans. Sciety, Capitainer’s long-term partner, played a key role in connecting the company to the new investor and participated in the funding round. Stockholm-based Capitainer, founded in 2013, has developed Capitainer qDBS, a disposable dried blood spot sampling chip that measures and stores an exact blood volume to enable quantitative measurements. The kit is designed for at-home use by non-healthcare professionals, eliminating common human error in sampling and allowing patients to mail samples to laboratories without refrigeration or specialised packaging. Capitainer positions the product for patients who need continuous monitoring and expects the solution to save travel and healthcare resources while improving patient experience and healthcare efficiency. The company highlights potential environmental benefits from reduced logistics requirements. To commercialise qDBS, Capitainer announced it closed a share issue of €1.39 million. Investors and company leadership describe the device as able to expand the existing dried blood spot market and to enter a larger clinical home sampling market.

Led · Convertible Note · Jan 2024

PharmNovo is a clinical-stage biotechnology company developing PN6047, a drug candidate that is advancing toward a Phase II study. The company recently completed a financing round of roughly 39 million kronor to fund that planned Phase II trial. KDventures AB, which holds PharmNovo in its portfolio, announced the capital raise and concurrently wrote down the book value of its holding to 5 million kronor. The financing included participation from external investors, though specific investor names beyond KDventures were not disclosed. No revenue, user metrics, or prior funding round details were provided in the articles.

Led · Equity · Jan 2023

Akiram Therapeutics is developing a targeted radioimmunotherapy that combines the company’s proprietary antibody with the radioactive compound lutetium‑177. Its lead candidate’s first indication is anaplastic thyroid cancer, where extensive preclinical studies showed tumours disappearing entirely after a single treatment in animal models. The company believes the candidate has potential to be first‑in‑class and to qualify as an orphan drug. Akiram also sees clinical potential in other thyroid and head‑and‑neck cancers. The team includes leading experts in radiation science, precision oncology and drug development, and is led by founder and CEO Marika Nestor. Recent financing gives the company resources to accelerate development and prepare for clinical trials, including an intended phase I study.